Dose response of enoxaparin at the cremaster muscle flap microcirculation

Microsurgery

Volumn 25, Issue 2, 2005, Pages 147-151

  Ertaş, Nilgün Markal ^a   Goldman, Corey ^a   Deitcher, Steven ^a   Siemionow, Maria ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CELL; BLOOD FLOW VELOCITY; CAPILLARY DENSITY; CONTROLLED STUDY; CREMASTER MUSCLE; DISSECTION; DOSE RESPONSE; ERYTHROCYTE; MALE; MICROCIRCULATION; MICROSCOPY; MUSCLE FLAP; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICOAGULANTS; BLOOD FLOW VELOCITY; CAPILLARIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; ERYTHROCYTES; MALE; MICROCIRCULATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 14644433625     PISSN: 07381085     EISSN: None     Source Type: Journal    
DOI: 10.1002/micr.20097     Document Type: Article

References (28)

1. Ritter EF, Cronan JC, Rudner AM, Serafm D, Klitzman B. Improved microsurgical anastomotic patency with low molecular weight heparin. J Reconstr Microsurg 1998;14:331-336.
2. Chen LE, Seaber AV, Korompilias AV, Urbaniak JR. Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. Microsurgery 1995;16:661-665.
3. Ibbotson T, Goa KL. Enoxaparin. An update of its clinical use in the management of acute coronary syndromes. Drugs 2002;62:1407-1431.
4. Bang CJ, Riedel B, Talstad I, Berstad A. Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans. Scand J Gastroenterol 1992;27:924-928.
5. Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613-625.
6. Korompilias AV, Chen LE, Seaber AV, Urbaniak JR. Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses. J Hand Surg [Am] 1997;22:540-546.
7. Libersan D, Khalil A, Dagenais P, Quan E, Delorme F, Uzan A, Latour JG. The low molecular weight heparin, enoxaparin, limits infarction size at reperfusion in the dog. Cardiovasc Res 1998;37:656-666.
8. Pratt J, Boudeau P, Uzan A, Imperato A, Stutzmann JM. Enoxaparin reduces cerebral edema after photothrombotic injury in the rat. Haemostasis 1988;28:78-85.
9. Kodak E, Yosipovitch G, David M, Ingber A, Chorev L, Lider O, Cahalon L, Cohen IR. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol 1998;38:564-568.
10. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001;46:2239-2244.
11. Wakefield AJ, Dhillon AP, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2:1057-1062.
12. Bang JB, Berstad A, Talstad I. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats. Haemostasis 1991;21:30-36.
13. Vela AR, Littleton JC, O'leary JP. The effects of minidose heparin and low molecular weight heparin on peritonitis in the rat. Am Surg 1999;65:473-477.
14. Anderson T, Acland RD, Siemionow M, McCabe SJ. Vascular isolation of the rat cremaster. Microvasc Res 1988;36:56-63.
15. Koopman MM, Prandomi P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-687.
16. Grosset AB, Spiro TE, Beynon J, Rodgers GM. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 1997;86:349-354.
17. Nilsson PE, Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, Nicolas S, Nylander G. The post-discharge prophylactic management of the orthopaedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics 1997;20:22-25.
18. Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998;13:81-89.
19. Bazzoni G, Beltran NA, Mascellani G, Bianchini P, Dejana E, Del Maschio A. Effect of heparin, dermatan sulfate and related oligoderivatives on human polymorphonuclear leukocyte function. J Lab Clin Med 1993;121:268-275.
20. Tyrrell DJ, Kilfeather S, Page DC. Heparin beyond its traditional role as an anticoagulant. TIPS 1993;16:198-204.
21. Ingber A, Trattner A, Cohen IR, Mekori YA. Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity. Acta Derm Venereol (Stockh) 1997;77:495-496.
22. Mazzoni MC, Schmid-Schönbein GW. Mechanisms and consequence of cell activation in the microcirculation. Cardiovasc Res 1996;32:709-719.
23. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
24. Chadwick VS, Ferry DM, Butt TJ. Assessment of neutrophil leukocyte secretory response to fMLP in whole blood in vitro. J Leukocyte Biol 1992;52:143-150.
25. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I. Inhibition of heparinase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-557.
26. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. Sticky neutrophil, pathergic arthritis and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-588.
27. Dotan I, Hershkoviz R, Karmeli F, Brazowski E, Peled Y, Rachmilewitz D, Halpern Z. Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. Aliment Pharmacol Ther 2001;15:1687-1697.
28. McClanahan TB, Hicks GW, Morrison AL, Peng YW, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser Jr, Juneau PL, Leadley R. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol 2001;432:187-194.